NTRA vs TEM
NTRA: Natera uses proprietary blood-based cell-free DNA technology to deliver personalized genetic diagnostics for oncology, prenatal screening, and organ transplant health. TEM: Tempus AI leverages a massive library of multimodal clinical and molecular data to power AI-driven precision medicine for patients and researchers.
Side-by-side fundamentals
| Metric | NTRA | TEM | Edge |
|---|---|---|---|
| Price as of 2026-07-31 close | $267.76 | $43.87 | |
| Market cap as of 2026-08-03 | $38.3B | $7.9B | |
| PEG as of 2026-08-03 | -13.76 | -1.42 | NTRA lower |
| Net margin as of 2026-08-03 | -9.1% | -22.2% | NTRA higher |
| Gross margin as of 2026-08-03 | +65.1% | +63.4% | NTRA higher |
| Operating margin as of 2026-08-03 | -13.0% | -20.6% | NTRA higher |
| ROE as of 2026-08-03 | -15.1% | -70.2% | NTRA higher |
| ROA as of 2026-08-03 | -10.5% | -14.6% | NTRA higher |
| Debt / equity as of 2026-08-03 | 0.05 | 2.96 | NTRA lower |
| Revenue growth (YoY) as of 2026-08-03 | +36.6% | +69.8% | TEM higher |
| Revenue CAGR (3y) SEC XBRL | +41.1% | +58.3% | TEM higher |
| Beta as of 2026-08-03 | 1.32 | 2.70 | |
| 1-year return as of 2026-07-31 close | +100.3% | -22.5% | NTRA higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-31.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.